Page 91 - Haematologica June

Dexamethasone in AML
Table 2. Patients’ outcomes during induction chemotherapy according to study group.
No dexamethasone n=100 (62.5%)
Admission in intensive care unit*– n (%)
No 83 (83.0) Yes 17 (17.0)
Bacterial infections - n (%)
No 71 (73.2) Yes 26 (26.8)
Fungal infections - n (%)
No 86 (88.7) Yes 11 (11.3)
Bleeding events (grade 3-4) - n (%)
No 91 (93.8) Yes 6 (6.2)
Day-60 deaths - n (%)
No 80 (80.0) Yes 20 (20.0)
Induction failure - n (%)
No 92 (92.0) Yes 8 (8.0)
Complete response - n (%)
No 26 (26.0) Yes 74 (74.0)
*During the first three months following chemotherapy.
A
Dexamethasone n=60 (37.5%)
31 (51.7) 29 (48.3)
38 (63.3)
22 (36.7)
52 (86.7) 8 (13.3)
47 (78.3)
13 (21.7)
53 (88.3) 7 (11.7)
57 (95.0)
3 (5.0) 10 (16.7)
50 (83.3)
P
<0.0001
0.192
0.710
0.004
0.173
0.538
0.171
All patients n=160
114 (71.3) 46 (28.8)
109 (69.4)
48 (30.6)
138 (87.9) 19 (12.1)
138 (87.9)
19 (12.1)
133 (83.1) 27 (16.9)
149 (93.1)
11 (6.9) 36 (22.5)
124 (77.5)
Figure 2. Estimates of survival end points and incidence of relapse. (A) Kaplan–Meier curves for overall survival in patients treated with dexamethasone (black line) or not (solid line in red). (B) Show event-free survival, (C) disease-free survival and (D) cumulative incidence of relapse. It is worth nothing that the follow up concern- ing relapse seems to be equal in the dexamethasone and no dexamethasone groups. This is due to the competing risk analyses. Indeed, in the competing risk analy- ses, a subject having a non-relapse death was not censored at the date of death and was still virtually considered to be at risk of having a relapse (and was still in follow up).
B
CD
haematologica | 2018; 103(6)
993